0.5200CAD+16.85%Mkt Cap: 35.33M CADP/E: —Last update: 2026-06-01
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which i…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap35.33M CAD
Enterprise Value32.41M CAD
Revenue (TTM)158.08K CAD
Gross Profit-450.37K CAD
Net Income (TTM)-1.55M CAD
Revenue/Share0.0020 CAD
Last Price0.5200 CAD
Fiscal Year EndSep 2025
MR QuarterDec 2025
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue205.05
P/S191.24
P/B-8.24
EPS (TTM)-0.04
EPS (Forward)—
52W Range
0.39008% of range1.950
52W High1.950 CAD
52W Low0.3900 CAD
Profitability
Gross Margin-284.90%
Oper. Margin-1481.29%
EBITDA Margin0.00%
Profit Margin0.00%
ROE40.00%
ROA-1485.45%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.53M CAD
CapEx (TTM)—
FCF Margin-481.62%
FCF Yield-2.16%
Net Debt2.63M CAD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.64
Current Ratio0.01
Quick Ratio0.00
Book Value/Sh-0.0540 CAD
Cash/Share0.0000 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateSep 13, 2000
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.67.93M
Float52.33M
Insiders19.17%
Institutions0.00%
Short Interest
Short Ratio0.3d
Short % Out.0.03%
Shares Short23.01K
Short (prev mo.)27.11K
Technical
SMA 500.4878 (+6.6%)
SMA 2001.015 (-48.7%)
Beta2.05
S&P 52W Chg27.70%
Avg Vol (30d)57.26K
Avg Vol (10d)34.00K
Technical Indicators
RSI (14)42.9
MACD-0.0146
MACD Signal-0.0223
MACD Hist.+0.0077
BB Upper0.4564 CAD
BB Middle0.4353 CAD
BB Lower0.4141 CAD
BB Width9.72%
ATR (14)0.0176 CAD
Vol Ratio (20d)1.44x